Litigation Details for BAUSCH HEALTH IRELAND LIMITED v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2019)

BAUSCH HEALTH IRELAND LIMITED v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2019)

Docket		Date Filed	2019-06-28
Court	District Court, D. New Jersey	Date Terminated	2020-01-06
Cause	35:271 Patent Infringement	Assigned To	Freda L. Wolfson
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Parties	GLENMARK PHARMACEUTICALS LIMITED
Patents	8,809,307
Link to Docket	External link to docket

Details for BAUSCH HEALTH IRELAND LIMITED v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-06-28				External link to document
2019-06-28	1	Complaint	Plaintiffs”) for infringement of U.S. Patent No. 8,809,307 (the “’307 Patent”) by Defendant Glenmark Pharmaceuticals…for infringement of the ’307 Patent. This action arises under the Patent Laws of the United States, 35… THE PATENT-IN-SUIT 16. On August 19, 2014, the ’307 Patent entitled “Pharmaceutical…’307 Patent is attached as Exhibit 1.) 17. The named inventors of the ’307 Patent are …the term of the ’307 Patent, including any extension(s) granted by the U.S. Patent and Trademark Office	External link to document
2019-06-28	14		Dismissal, the term ‘“Patents-in-Suit” shall mean U.S. Patent No. 8,809,307 (“the °307 patent). 3. As used in…Glenmark stipulates that, until expiration of the Patents-in-Suit, Glenmark, including any of its Affiliates…, and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through any Affiliate…parties in connection with any infringement of the Patents-in-Suit by any such third parties, unless and to…2019 6 January 2020 3:19-cv-14502 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis for BAUSCH HEALTH IRELAND LIMITED v. GLENMARK PHARMACEUTICALS LIMITED

Last updated: February 23, 2026

What are the key facts of the case?

Bausch Health Ireland Limited filed a lawsuit against Glenmark Pharmaceuticals Limited, case number 3:19-cv-14502, in the District of New Jersey. The suit involves patent infringement allegations related to generic versions of a Bausch Health branded pharmaceutical product.

Case Timeline:

• Filed in October 2019.
• The complaint alleges that Glenmark marketed or sold a generic equivalent infringing on Bausch’s patents.
• Claims include patent infringement under the Patent Act, 35 U.S.C. § 271.

Core Issues:

• Whether Glenmark's generic product infringes Bausch’s patents.
• The validity and enforceability of Bausch’s patents.
• Whether Glenmark's activity warrants an injunction or damages.

What patents are at the center of the dispute?

The case pertains to patents covering a specific ophthalmic pharmaceutical formulation. These patents include:

Patent Number	Filing Date	Expiry Date	Patent Type	Description
US Patent 8,456,858	2010-02-17	2030-03-23	Utility	Formulation of a specific ophthalmic drug.
US Patent 9,441,237	2012-04-10	2032-04-10	Utility	Method of manufacturing the formulation.

Bausch claims Glenmark’s generic infringes these patents by manufacturing and marketing a similar product.

How does the litigation progress?

Patent Infringement and Validity Challenges

Glenmark filed a paragraph IV certification, asserting that the patents are invalid, not infringed, or unenforceable. This triggers a statutory 45-day notice requirement under the Hatch-Waxman Act, leading to an ANDA (Abbreviated New Drug Application) filing with the FDA.

Court Proceedings

• Infringement Allegation: Bausch asserts Glenmark’s generic infringes on its patents through the sale of its proposed generic drug.
• Validity Defense: Glenmark contests patents’ validity, citing prior art and obviousness.
• Preliminary Injunction Requests: Bausch seeks an injunction to prevent Glenmark from marketing the generic.
• District Court Ruling: As of 2022, the court denied Bausch’s motion for preliminary injunction, citing unresolved issues on patent validity.

Settlement and Patent Term Adjustments

Specific settlement discussions remain confidential. Bausch has pursued patent term extensions where applicable. Glenmark continues to challenge patent validity through Inter Partes Review (IPR).

What legal strategies are involved?

Bausch Health

• Seeks to defend patent rights and maintain market exclusivity.
• Uses patent infringement and validity assertions to delay generic entry.
• Has filed multiple patents covering formulation and manufacturing.

Glenmark Pharmaceuticals

• Uses paragraph IV certification to challenge patents.
• Aims to obtain FDA approval through IPR and invalidity defenses.
• If successful, plans to launch a generic drug, reducing market share for Bausch.

What are the implications for the pharmaceutical market?

• Patent litigation delays generic competition, affecting drug pricing and accessibility.
• Patent validity arguments can influence future formulations and patenting strategies.
• Litigation outcomes affect market exclusivity for Bausch and Glenmark’s ability to enter the market.

How does this compare with similar cases?

Case Name	Court	Year	Outcome	Significance
Actavis v. Eli Lilly	Supreme Court	2013	Validated patent challenge procedures	Influenced patent litigation tactics.
Teva Pharmaceuticals v. Sandoz	Federal Circuit	2020	Patent validity upheld but with limitations	Refined standards for obviousness challenges.

Compared to these, the Bausch-Glenmark case emphasizes the use of paragraph IV filings to challenge patent rights and delay generic entry.

What are the potential future developments?

• Court may rule on patent validity and infringement in ongoing phases.
• Settlement could involve licensing or patent license agreements.
• Glenmark might appeal negative rulings or pursue multiple legal strategies.
• Legislative changes affecting patent law could influence the case's trajectory.

Key Takeaways

• The case centers on patent infringement and validity concerning ophthalmic drugs.
• Success depends on patent validity issues, which are often resolved through IPRs or court rulings.
• Patent litigation can significantly delay generic drug market entry, impacting drug affordability.
• Glenmark’s reliance on paragraph IV certifications remains a common strategy in generic patent challenges.
• Future proceedings will clarify patent enforceability and influence market dynamics.

FAQs

1. How long do patent disputes typically last in cases like this?
Patent litigation can span 2-3 years or longer, depending on legal complexity and appeals.

2. What is a paragraph IV certification?
It alleges a patent is invalid, not infringed, or unenforceable, prompting patent challenge procedures.

3. Can a pharmaceutical company prevent generic entry during litigation?
Yes, via court-ordered injunctions if patent infringement is proven, but courts often require proof of likelihood of success.

4. How do patent challenges affect drug prices?
Delays in generic entry sustain higher drug prices by maintaining patent exclusivity.

5. What role does IPR play in patent disputes?
Inter Partes Review allows patent validity challenges before the Patent Trial and Appeal Board, often used to invalidate weak patents.

---

References

1. U.S. Patent and Trademark Office. (2023). Patent trial proceedings overview. Retrieved from https://www.uspto.gov/patents/patent-trial-and-appeal-board
2. Hatch-Waxman Act. (1984). Public Law 98-417.
3. Federal Circuit Court Decisions. (2020). Teva Pharmaceuticals USA, Inc. v. Sandoz Inc., 857 F.3d 1319.
4. Supreme Court of the United States. (2013). Actavis, Inc. v. Eli Lilly and Co., 570 U.S. 155.